CA
CanSino Biologics Inc.
CASBF · OTC
$3.90 +32.20% (+$0.95)
Market Cap ¥6.92B
P/E Ratio 170.18x
Div. Yield -
ROE 0.82%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
20 /100
Expensive EV/EBITDA 87.49x
P/S 5.64x
P/B 1.39x
Growth
16 /100
Declining Book val. growth 9.78%
Rev. growth 0.03%
FCF growth N/A
Profitability
25 /100
Weak Net margin 3.31%
Op. margin 4.62%
FCF margin 10.46%
Quality
4 /100
Poor ROE 0.82%
ROA 0.59%
Asset turnover 0.18x
Debt
80 /100
Low Current ratio 4.39x
Int. coverage -0.66x
Net debt/EBITDA -2.51x
Stability
21 /100
Unstable Rev. volatility 102.95%
EPS volatility 90.25%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CASBF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Xue Feng Yu
Employees
1,134
Headquarters
Tianjin
Upcoming events
02 NOV
Earnings
Upcoming earnings report
30 MAR
Earnings
Upcoming earnings report